Portola: A Small Biotech Stock That Could Double - And Then Double Again
- Portola Pharmaceuticals is an 11-year old biotech-biopharma company operating in the heme-onc field.
- Its specific area of focus involves Factor Xa inhibition.
- Its most exciting product is andexanet, a universal antidote to bleeding caused by inhibiting Factor Xa.
- While there are numerous and serious risks, the upside from andexanet appears reasonably well-defined to me.